CIBELE LARROSA GARZILLO
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
11 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 11
conferenceObject EFFECT OF MYOCARDIAL ISCHEMIA IN DIABETIC AND NON-DIABETIC PATIENTS: LONG-TERM FOLLOW-UP OF MASS REGISTRY(2020) CARVALHO, Felipe Pereira Camara de; HUEB, Whady; LIMA, Eduardo Gomes; LINHARES FILHO, Jaime; RIBEIRO, Matheus; MARTINS, Eduardo; BATISTA, Daniel Valente; GARZILLO, Cibele; BOROS, Gustavo Andre Boeing; REZENDE, Paulo; RIBAS, Fernando Faglioni; SERRANO, Carlos; RAMIRES, Jose; KALIL-FILHO, Roberto- Stress Testing and Risk Prediction in People With Known Symptomatic Multivessel Coronary Artery Disease Reply(2020) GARZILLO, Cibele Larrosa; REZENDE, Paulo Cury; HUEB, Whady
conferenceObject Effect of myocardial ischemia in diabetic and non-diabetic patients: long-term follow-up of MASS registry(2020) CARVALHO, F. Camara De; HUEB, W.; LIMA, E. G.; LINHARES FILHO, J. P. P.; RIBEIRO, M. O. L.; MARTINS, E. B.; V, D. Batista; GARZILLO, C. L.; RIBAS, F. F.; BOROS, G. A. B.; REZENDE, P. C.; V, C. Serrano Junior; RAMIRES, J. A. F.; KALIL FILHO, R.- Occurrence of recently diagnosed atrial fibrillation in the immediate postoperative period of myocardial revascularization surgery. Although common, a devalued complication(2020) PEREIRA, Marcel de Paula; LIMA, Eduardo Gomes; GARZILLO, Cibele Larrosa; BARBOSA, Camila Talita Machado; SAMPAIO, Leon Pablo Cartaxo; DARRIEUX, Francisco Carlos da Costa; SERRANO JR., Carlos VicenteAtrial fibrillation (AF) is the most common arrhythmia in the postoperative period of cardiac surgery, with a prevalence between 15-40% after coronary artery bypass surgery (CABG). Several strategies have been tested for the prevention and management of AF postoperatively. Previous studies and analysis of records have shown higher rates of hospitalization and clinical outcomes associated with this entity, including increased mortality in the short- and long-term. This perspective reviews the topic, and offers recommendations for the management of this arrhythmia in the postoperative period of CABG, with a special focus on anticoagulation strategies.
conferenceObject CHARACTERIZATION, TREATMENT AND OUTCOMES OF PATIENTS WITH STABLE ISCHEMIC HEART DISEASE IN A TERTIARY-CARE CENTER IN BRAZIL(2020) MOREIRA, Eduardo; GARZILLO, Cibele; AYRES, Sandra; FAVARATO, Desiderio; PITTA, Fabio; LIMA, Eduardo Gomes; HUEB, Whady; SERRANO, CarlosconferenceObject Gender-related Differences in the Management of Chronic Coronary Syndrome: Registry Data of a Tertiary Center in Brazil(2020) SERRANO, Carlos V.; MOREIRA, Eduardo M.; GARZILLO, Cibele L.; MONTENEGRO, Luiz M.; TABUSE, Cindy L.; KORMANN-MOREIRA, Mylena C.; SEGRE, Alexandre W.; BOLTA, Paula M.; FAVARATO, Desiderio; PITTA, Fabio G.; LIMA, Eduardo G.; REZENDE, Paulo H.; HUEB, Whady A.- Association of Longitudinal Values of Glycated Hemoglobin With Cardiovascular Events in Patients With Type 2 Diabetes and Multivessel Coronary Artery Disease(2020) REZENDE, Paulo Cury; HLATKY, Mark Andrew; HUEB, Whady; GARCIA, Rosa Maria Rahmi; SELISTRE, Luciano da Silva; LIMA, Eduardo Gomes; GARZILLO, Cibele Larrosa; SCUDELER, Thiago Luis; BOROS, Gustavo Andre Boeing; RIBAS, Fernando Faglioni; SERRANO, Carlos Vicente; RAMIRES, Jose Antonio Franchini; KALIL FILHO, RobertoQuestion Are longitudinal glycated hemoglobin values associated with cardiovascular events in patients with type 2 diabetes and stable multivessel coronary artery disease? Findings In this cohort study of 725 patients with type 2 diabetes and multivessel coronary artery disease, a 1-point increase in glycated hemoglobin values during follow-up was independently associated with higher risk of the combined outcome of death, myocardial infarction, or ischemic stroke, after adjustment for baseline clinical factors. Meaning Longitudinal increase of glycated hemoglobin was associated with higher rates of cardiovascular events in patients with type 2 diabetes and multivessel coronary artery disease, and the mechanisms underlying this association require further investigation. This cohort study examines whether longitudinal variation of glycated hemoglobin (HbA(1c)) is associated with cardiovascular events in patients with diabetes and multivessel coronary artery disease (CAD). Importance Glycated hemoglobin (HbA(1c)) values are used to guide glycemic control, but in patients with type 2 diabetes and multivessel coronary artery disease (CAD), the association of the longitudinal values of HbA(1c) with cardiovascular outcomes is unclear. Objective To assess whether longitudinal variation of HbA(1c) is associated with cardiovascular events in long-term follow-up among patients with diabetes and multivessel CAD. Design, Setting, and Participants This cohort study included 888 patients with type 2 diabetes and multivessel CAD in the Medicine, Angioplasty, or Surgery Study (MASS) Registry of the Heart Institute of the University of Sao Paulo from January 2003 to December 2007. Data were analyzed from January 15, 2018, to October 15, 2019. Exposure Longitudinal HbA(1c) values. Main Outcomes and Measures The combined outcome of all-cause mortality, myocardial infarction, and ischemic stroke. Results Of 888 patients with type 2 diabetes and multivessel CAD, 725 (81.6%; median [range] age, 62.4 [55.7-68.0] years; 467 [64.4%] men) had complete clinical and HbA(1c) information during a median (interquartile range) follow-up period of 10.0 (8.0-12.3) years, with a mean (SD) of 9.5 (3.8) HbA(1c) values for each patient. The composite end point of death, myocardial infarction, or ischemic stroke occurred in 262 patients (36.1%). A 1-point increase in the longitudinal value of HbA(1c) was significantly associated with a 14% higher risk of the combined end point of all-cause mortality, myocardial infarction, and ischemic stroke (hazard ratio, 1.14; 95% CI, 1.04-1.24; P = .002) in the unadjusted analysis. After adjusting for baseline factors (ie, age, sex, 2-vessel or 3-vessel CAD, initial CAD treatments, ejection fraction, and creatinine and low-density lipoprotein cholesterol levels), a 1-point increase in the longitudinal value of HbA(1c) was associated with a 22% higher risk of the combined end point (hazard ratio, 1.22; 95% CI, 1.12-1.35; P < .001). Conclusions and Relevance Longitudinal increase of HbA(1c) was independently associated with higher rates of cardiovascular events in patients with type 2 diabetes and multivessel CAD.
- Neither Moderate Consumption of Sugarcane Liquor (""Cachaca"") Nor of Red Wine Affect Cardiovascular Risk Biomarkers in Healthy Individuals(2020) CELLIA, Pedro H.; LIMA, Eduardo G.; MOREIRA, Eduardo; BARBOSA, Livia B.; PITTA, Fabio G.; RACHED, Fabiana H.; STRUNZ, Celia M.; FAVARATO, Desiderio; GARZILLO, Cibele L.; SERRANO, Carlos V.
- Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial(2020) LIMA, Eduardo Gomes; CHARYTAN, David M.; HUEB, Whady; AZEVEDO, Diogo Freitas Cardoso de; GARZILLO, Cibele Larrosa; FAVARATO, Desiderio; LINHARES FILHO, Jaime Paula Pessoa; MARTINS, Eduardo Bello; BATISTA, Daniel Valente; REZENDE, Paulo Cury; HUEB, Alexandre Ciappina; RAMIRES, Jose Antonio Franchini; KALIL FILHO, RobertoBackground. Chronic kidney disease (CKD) is associated with a worse prognosis in patients with stable coronary artery disease (CAD); however, there is limited randomized data on long-term outcomes of CAD therapies in these patients. We evaluated long-term outcomes of CKD patients with CAD who underwent randomized therapy with medical treatment (MT) alone, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG). Methods. Baseline estimated glomerular filtration rate (eGFR) was obtained in 611 patients randomized to one of three therapeutic strategies in the Medicine, Angioplasty, or Surgery Study II trial. Patients were categorized in preserved renal function and mild or moderate CKD groups depending on their eGFR (>= 90, 89-60 and 59-30 mL/min/1.73 m(2), respectively). The primary clinical endpoint, a composite of overall death and myocardial infarction, and its individual components were analyzed using proportional hazards regression (Clinical Trial registration information: http://www.controlled-trials.com.Registration number: ISRCTN66068876). Results. Of 611 patients, 112 (18%) had preserved eGFR, 349 (57%) mild dysfunction and 150 (25%) moderate dysfunction. The primary endpoint occurred in 29.5, 32.4 and 44.7% (P = 0.02) for preserved eGFR, mild CKD and moderate CKD, respectively. Overall mortality incidence was 18.7, 23.8 and 39.3% for preserved eGFR, mild CKD and moderate CKD, respectively (P = 0.001). For preserved eGFR, there was no significant difference in outcomes between therapies. For mild CKD, the primary event rate was 29.4% for PCI, 29.1% for CABG and 41.1% for MT (P = 0.006) [adjusted hazard ratio (HR) = 0.26, 95% confidence interval (CI) 0.07-0.88; P = 0.03 for PCI versus MT; and adjusted HR = 0.48; 95% CI 0.31-0.76; P = 0.002 for CABG versus MT]. We also observed higher mortality rates in the MT group (28.6%) compared with PCI (24.1%) and CABG (19.0%) groups (P = 0.015) among mild CKD subjects (adjusted HR = 0.44, 95% CI 0.25-0.76; P = 0.003 for CABG versus MT; adjusted HR = 0.56, 95% CI 0.07-4.28; P = 0.58 for PCI versus MT). Results were similar with moderate CKD group but did not achieve significance. Conclusions. Coronary interventional therapy, both PCI and CABG, is associated with lower rates of events compared with MT in mild CKD patients >10 years of follow-up. More study is needed to confirm these benefits in moderate CKD.
conferenceObject T1 MAPPING AND EXTRACELLULAR VOLUME FOR THE EVALUATION OF MYOCARDIAL INTERSTITIAL MATRIX IN DIABETIC AND NON-DIABETIC PATIENTS WITH MULTIVESSEL CORONARY ARTERY DISEASE(2020) BOROS, Gustavo Andre Boeing; HUEB, Whady; REZENDE, Paulo; NOMURA, Cesar; ROCHITTE, Carlos; RIBEIRO, Matheus; DALLAZEN, Anderson Roberto; RIBAS, Fernando Faglioni; MORAIS, Thamara; LIMA, Eduardo Gomes; GARZILLO, Cibele; SERRANO, Carlos; RAMIRES, Jose; KALIL-FILHO, Roberto